CLIMB BIO, INC. Restructuring Charges
CLIMB BIO, INC. (CLYM) reported Restructuring Charges of $0 for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2024-05-15
- CLIMB BIO, INC. restructuring charges for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- CLIMB BIO, INC. restructuring charges for the quarter ending 2023-12-31 was $2.00M.
- CLIMB BIO, INC. restructuring charges for the quarter ending 2023-09-30 was $200.00K.
- CLIMB BIO, INC. restructuring charges for the quarter ending 2023-06-30 was $700.00K.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | $2.00M derived: sum of 2 quarters · filed 2024-05-15 | $2.20M derived: sum of 3 quarters · filed 2024-05-15 | $2.90M derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-12-31 | $2.00M 10-K · filed 2024-03-28 | $2.20M derived: sum of 2 quarters · filed 2024-03-28 | $2.90M derived: sum of 3 quarters · filed 2024-03-28 | $18.70M derived: sum of 4 quarters · filed 2024-03-28 |
| 2023-09-30 | $200.00K 10-Q · filed 2023-11-14 | $900.00K derived: sum of 2 quarters · filed 2023-11-14 | $16.70M derived: sum of 3 quarters · filed 2023-11-14 | |
| 2023-06-30 | $700.00K 10-Q · filed 2023-08-10 | $16.50M derived: sum of 2 quarters · filed 2023-08-10 | ||
| 2023-03-31 | $15.80M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |